A5026388140- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Pregnancy and preeclampsia studies
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Issues in Pregnancy
- Central Venous Catheters and Hemodialysis
- Platelet Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Proteoglycans and glycosaminoglycans research
- Acute Myocardial Infarction Research
- Hemophilia Treatment and Research
- Maternal and fetal healthcare
- Extracellular vesicles in disease
- Diagnosis and Treatment of Venous Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood properties and coagulation
- Cancer Risks and Factors
- Acute Lymphoblastic Leukemia research
- Acute Ischemic Stroke Management
- Blood disorders and treatments
- Angiogenesis and VEGF in Cancer
- Antiplatelet Therapy and Cardiovascular Diseases
- Protease and Inhibitor Mechanisms
- Systemic Lupus Erythematosus Research
Rambam Health Care Campus
2016-2025
Technion – Israel Institute of Technology
2014-2024
Sechenov University
2020-2024
Rappaport Family Institute for Research in the Medical Sciences
1997-2023
Haifa Medical Center
2014-2023
Ospedale Buon Consiglio Fatebenefratelli
2023
Hospital Regional Universitario de Málaga
2022
Hôpital Rangueil
2020
Hospital Universitari Germans Trias i Pujol
2015-2020
Universitat Autònoma de Barcelona
2020
Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and continued treatment, without the need laboratory monitoring.
The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial.In a randomized, double-blind trial, we compared tenecteplase plus heparin placebo normotensive embolism. Eligible had right ventricular dysfunction on echocardiography or computed tomography, as well myocardial injury indicated by positive test for cardiac troponin I T. primary outcome was death hemodynamic decompensation (or collapse) within 7 days after randomization. main safety...
Recent guidelines recommend consideration of the use oral edoxaban or rivaroxaban for treatment venous thromboembolism in patients with cancer. However, benefit these agents is limited by increased risk bleeding associated their use.This was a multinational, randomized, investigator-initiated, open-label, noninferiority trial blinded central outcome adjudication. We randomly assigned consecutive cancer who had symptomatic incidental acute proximal deep-vein thrombosis pulmonary embolism to...
The efficacy and safety of anticoagulant treatment for patients with acute, symptomatic superficial-vein thrombosis in the legs, but without concomitant deep-vein or pulmonary embolism at presentation, have not been established.In a randomized, double-blind trial, we assigned 3002 to receive either fondaparinux, administered subcutaneously dose 2.5 mg once daily, placebo 45 days. primary outcome was composite death from any cause embolism, thrombosis, extension saphenofemoral junction...
Abstract Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a preventable cause of in-hospital death, one the most prevalent vascular diseases. There lack knowledge with regards to contemporary presentation, management outcomes patients VTE. Many clinically important subgroups (including elderly, those recent bleeding pregnant patients) have been under-represented in clinical trials. Furthermore, design trials challenging some scenarios, such...
Venous and arterial thromboembolism occurs in only about one third of patients homozygous for homocystinuria, which suggests that other, contributory factors are necessary the development thrombosis these patients. Factor V Leiden, an R506Q mutation gene coding factor V, is most common cause familial could be a potentiating factor.We determined activated partial-thromboplastin times presence absence protein C tested Leiden 45 members seven unrelated consanguineous kindreds at least 1 member...
The relative importance of previous diagnosis and hereditary prothrombotic risk factors for cerebral venous thrombosis (CVT) in children determining a second or systemic (VT), compared with other clinical, neuroimaging, treatment variables, is unknown.We followed up the survivors 396 consecutively enrolled patients CVT, aged newborn to 18 years (median 5.2 years) median 36 months (maximum 85 months). In accordance international guidelines, 250 (65%) received acute anticoagulation...
Abstract International and national guidelines recommend low-molecular-weight heparin for the treatment of venous thromboembolism (VTE) in patients with cancer. The aim Caravaggio study is to assess whether oral apixaban non-inferior subcutaneous dalteparin acute proximal deep vein thrombosis and/or pulmonary embolism an investigator-initiated, multi-national, prospective, randomized, open-label blind end-point evaluation (PROBE), non-inferiority clinical trial (NCT03045406). Consecutive are...
Summary Type 2 diabetes mellitus (T2DM) is associated with increased coagulability and vascular complications. Circulating microparticles (MPs) are involved in thrombosis, inflammation, angiogenesis. However, the role of MPs T2DM complications unclear. We characterised cell origin pro-coagulant profiles obtained from 41 healthy controls 123 patients coronary artery disease, retinopathy foot ulcers. The effects on endothelial tube formation were evaluated. Patients severe diabetic ulcers...
Historically, the vaccination strategies developed in second half of 20th century have facilitated eradication infectious diseases. From onset COVID-19 pandemic to end April 2021, more than 150 million cases and 3 deaths were documented worldwide with disruption economic social activity, devastating material, physical, psychological consequences. Reports unusual severe thrombotic events, including cerebral splanchnic venous thrombosis other autoimmune adverse reactions, such as immune...